Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $1.36 which represents a decrease of $-0.03 or -2.16% from the prior close of $1.39. The stock opened at $1.41 and touched a low ...

Citigroup has recently resumed Mersana Therapeutics Inc (MRSN) stock to Buy rating, as announced on November 15, 2024, according to Finviz. Earlier, on March 19, 2024, JP Morgan had raised the stock ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight ...

Orphan Drug Tag For Mersana's Gastric Cancer Candidate Vandana Singh Mersana Therapeutics Director Andrew Hack Reported Purchase of 350,000 Shares @ Avg Price of $3.25/Share in Form 4 Filing on ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $-0.17.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

Mersana Therapeutics, Inc. has a twelve month low of $1.22 and a twelve month high of $6.28. The company’s 50-day moving average price is $2.17 and its 200-day moving average price is $1.97.